thiazoles has been researched along with pioglitazone in 400 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.25) | 18.7374 |
| 1990's | 128 (32.00) | 18.2507 |
| 2000's | 262 (65.50) | 29.6817 |
| 2010's | 8 (2.00) | 24.3611 |
| 2020's | 1 (0.25) | 2.80 |
| Authors | Studies |
|---|---|
| Egawa, K; Iwanishi, M; Kobayashi, M; Shigeta, Y | 1 |
| Clarke, SD; Foellmi, LA; Harris, PK; Kletzien, RF; Wyse, BM | 1 |
| Colca, JR; Hofmann, CA | 1 |
| Clarke, SD; Kletzien, RF; Ulrich, RG | 1 |
| Fujita, T; Ikeda, H; Meguro, K; Mizuno, K; Momose, Y; Sohda, T | 1 |
| Colca, JR; Edwards, CW; Hillman, RM; Hofmann, CA | 1 |
| Colca, JR; Dailey, CF; Dinh, DM; Hillman, RM; Melchior, GW; Palazuk, BJ; Spilman, CH | 1 |
| Colca, JR; Hofmann, C; Lorenz, K | 1 |
| Hatanaka, C; Ikeda, H; Meguro, K; Momose, Y; Oi, S; Sohda, T | 1 |
| Fujita, T; Ikeda, H; Shimura, Y; Sugiyama, Y; Taketomi, S | 1 |
| Ikeda, H; Shimura, Y; Sugiyama, Y | 1 |
| Fujita, T; Ikeda, H; Meguro, K; Shimura, Y; Sohda, T; Sugiyama, Y; Taketomi, S | 1 |
| Ikeda, H; Kawamatsu, Y; Meguro, K; Momose, Y; Sohda, T; Sugiyama, Y | 1 |
| Lakings, DB; Zhong, WZ | 1 |
| Polonsky, KS; Pugh, WL; Sturis, J; Tang, J | 1 |
| Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L | 1 |
| Bleasdale, JE; Jacob, CS; Sizer, KM; Smith, CL; Swanson, ML | 2 |
| Egawa, K; Hasegawa, M; Ide, R; Iwanishi, M; Kashiwagi, A; Kikkawa, R; Maegawa, H; Shigeta, Y; Ugi, S | 1 |
| Fukuda, H; Iritani, N | 1 |
| Buchanan, TA; Chan, TM; Hsueh, WA; Jeng, YY; Meehan, WP; Nadler, JL; Rude, RK; Scott, S; Yang, D | 1 |
| de Souza, CJ; Meglasson, MD; Robinson, DD; Ulrich, RG; Yu, JH | 1 |
| DeGrange, LM; Kaufman, LN; Peterson, MM | 1 |
| Fagnant, PM; Hirshman, MF; Horton, ED; Horton, ES; King, PA | 1 |
| Colca, JR; Hofmann, C; Lorenz, K; Palazuk, BJ; Williams, D | 1 |
| Daimon, M; Eguchi, H; Igarashi, M; Matsumoto, M; Sasaki, H; Sekikawa, A; Tominaga, M; Yamatani, K | 1 |
| Berger, J; Diaz, E; Hayes, N; Smith, R; Szalkowski, D; Zhang, B | 1 |
| Kotchen, TA; Reddy, SR; Zhang, HY | 1 |
| Nadler, J; Scott, S | 1 |
| Peuler, JD; Ram, JL; Sowers, JR; Standley, PR; Zhang, F | 1 |
| Colca, JR; Kurowski, TG; Ruderman, NB; Saha, AK | 1 |
| el-Kebbi, IM; Pollet, RJ; Roser, S | 1 |
| Harris, PK; Kletzien, RF | 1 |
| Boegehold, MA; Dubey, RK; Kotchen, TA; Reddy, SR; Zhang, HY | 1 |
| Braithwaite, SS; Colca, JR; Hofmann, C; Hotamisligil, GS; Lorenz, K; Palazuk, BJ; Spiegelman, BM | 1 |
| Egawa, K; Iwanishi, M; Kashiwagi, A; Kikkawa, R; Maegawa, H; Shigeta, Y; Tachikawa-Ide, R; Ugi, S | 1 |
| Baum, ST; Bergman, RN; Elson, DF; Kemnitz, JW; Meglasson, MD; Roecker, EB | 1 |
| Colca, JR; Kostyo, JL; Towns, R | 1 |
| Hofmann, C; Reda, D; Sandouk, T | 2 |
| Iwanishi, M; Kobayashi, M | 1 |
| Bleasdale, JE; Swanson, ML | 1 |
| Haber, RS; Holand, A; O'Boyle, E; Weinstein, SP | 1 |
| Castle, CK; Colca, JR; Melchior, GW | 1 |
| Brun, RP; Chen, J; Evans, RM; Forman, BM; Spiegelman, BM; Tontonoz, P | 1 |
| Umeda, F | 1 |
| Ikeda, H; Meguro, K; Sohda, T | 1 |
| Colca, JR; Corkey, BE; Cunningham, BA; Holbert, RI; Kurowski, TG; Ruderman, NB; Saha, AK | 1 |
| Amano, N; Ebara, T; Hirano, T; Hozumi, T; Ishida, Y; Kazumi, T; Odaka, H; Yoshino, G | 1 |
| Hayakawa, T; Ikeda, H; Morimoto, T; Shii, K; Shiraki, T | 1 |
| Imamura, T; Kobayashi, M; Morioka, H; Sawa, T; Takada, Y; Takata, Y; Yang, GH | 1 |
| Lambe, KG; Tugwood, JD | 1 |
| Mori, M; Ohtani, K; Sato, N; Shimizu, H; Tanaka, Y | 1 |
| Williams, MG; Zhong, WZ | 1 |
| Foellmi-Adams, LA; Herron, D; Kletzien, RF; Nedergaard, J; Wyse, BM | 1 |
| Auwerx, J; Briggs, MR; De Vos, P; Guerre-Millo, M; Hamann, LG; Lefebvre, AM; Miller, SG; Saladin, R; Staels, B; Wong, K | 1 |
| Hoffmann, RG; Kotchen, TA; Reddy, S; Zhang, HY | 1 |
| Cialdella, JI; Johnson, RA; Li, GP; Liggett, WF; Marshall, VP; Nidy, EG; Sih, JC | 1 |
| Fulgencio, JP; Girard, J; Kohl, C; Pégorier, JP | 1 |
| Kawamori, R; Yoshii, H | 1 |
| Hodorek, MJ; Iannucci, AR; Peuler, JD; Phare, SM | 1 |
| Motohashi, M; Murakami, H; Okuda, T; Yamashita, K | 1 |
| Gimble, JM; McAveney, KM; Yu-Lee, L | 1 |
| Colca, JR; Fisher, RM; Kletzein, RF; Parker, TT; Tanis, SP | 1 |
| Altiok, S; Brun, RP; Evans, RM; Fletcher, CD; Fletcher, JA; Forman, BM; Mueller, E; Oppenheim, H; Sarraf, P; Singer, S; Spiegelman, BM; Tontonoz, P | 1 |
| Connell, J; Petrie, J; Small, M | 1 |
| Giacca, A; Kawamori, R; Lekas, M; Matsuhisa, M; Rodgers, CD; Shi, ZQ; Vranic, M; Wan, C | 1 |
| Hashimoto, A; Kiyota, Y; Kondo, T; Maeshiba, Y; Motohashi, M; Tanayama, S; Yamashita, K; Yoshimura, Y | 1 |
| Kiyota, Y; Maeshiba, Y; Motohashi, M; Tanayama, S; Yamashita, K; Yoshimura, Y | 1 |
| Inoue, I; Katayama, S; Komoda, T; Miyazaki, T; Negishi, K; Sonoda, M; Takahashi, K | 1 |
| Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS | 1 |
| Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T | 1 |
| Fujita, H; Hatta, T; Itoh, H; Kawa, T; Kiyama, M; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Nakamura, K; Nakata, T; Sasaki, S; Takeda, K; Uchida, A | 1 |
| Altiok, S; Spiegelman, BM; Xu, M | 1 |
| Morimoto, Y; Nishikawa, K; Ohashi, M | 1 |
| Auwerx, J; Berthault, MF; Doaré, L; Dugail, I; Ferré, P; Foufelle, F; Guerre-Millo, M; Hallakou, S; Kergoat, M; Morin, J | 1 |
| Cwik, C; Mishra, SK; Postlethwaite, AE; Rajanna, B; Solomon, SS | 1 |
| Ikeda, H; Nomura, C; Odaka, H; Suzuki, M | 1 |
| Peraldi, P; Spiegelman, BM; Xu, M | 1 |
| Bourghli, M; Miller, JA; Peuler, JD; Soltis, EE; Sowers, JR; Zammam, HY | 1 |
| Kotchen, TA; Reddy, S; Zhang, HY | 1 |
| Imano, E; Kajimoto, Y; Kanda, T; Kawamori, R; Yamasaki, Y | 1 |
| Igarashi, M; Ishibashi, N; Mori, S; Saito, Y; Takahashi, K; Takeda, Y; Tominaga, M | 1 |
| Hirose, T; Kasayama, S; Kishimoto, T; Kurebayashi, S; Miyashita, Y | 1 |
| Inoue, Y; Nishimura, Y; Oka, Y; Takeuchi, H | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Ikeda, H; Odaka, H; Sohda, T; Sugiyama, Y | 1 |
| Baba, S; Kaneko, T | 1 |
| Kitaoka, H | 2 |
| Hari, J | 1 |
| Arikawa, E; Bhanot, S; McNeill, JH; Verma, S; Yao, L | 1 |
| Ikeda, H; Murase, K; Odaka, H; Suzuki, M; Tayuki, N | 1 |
| Baba, S; Eguchi, H; Hozumi, T; Ikeda, M; Ishida, Y; Kaneko, T; Kawamori, R; Kubota, M; Omori, Y; Sasaki, H; Sato, A; Shichiri, M; Tominaga, M; Uehara, M; Wasada, T; Yamasaki, Y | 1 |
| Kashiwagi, A; Kikkawa, R; Maegawa, H; Obata, T; Pillay, TS | 1 |
| Khandelwal, RL; Pugazhenthi, S | 1 |
| Breider, MA; Gralinski, MR; Rowse, PE | 1 |
| Ishizawa, M; Ishizuka, T; Itaya, S; Kajita, K; Kanoh, Y; Kimura, M; Miura, A; Muto, N; Wada, H; Yasuda, K | 1 |
| Doaré, L; Ferré, P; Foufelle, F; Hallakou, S; Kergoat, M | 1 |
| Fujiyama, K; Ikeda, T | 1 |
| Arisaka, T; Ikebuchi, M; Ikeda, M; Kanda, T; Kawamori, R; Kinoshita, J; Kubota, M; Matsuhisa, M; Mochizuki, K; Niwa, M; Tohdo, R; Wada, M; Yamasaki, Y | 1 |
| Cummings, R; Elbrecht, A; Hermes, JD; Li, Y; Mitra, S; Moller, DE; Schaeffer, JM; Smith, RG; Wilkinson, HA; Zhou, G | 1 |
| Baillie, RA; Clarke, SD; Sha, X; Thuillier, P | 1 |
| Hashimoto, S; Hirayama, R; Kato, M; Kurosaki, E; Shikama, H; Shimokawa, T; Watanabe, Y | 1 |
| Doi, K; Hanaoka, I; Hosoda, K; Inoue, G; Itoh, H; Matsuda, J; Nakao, K; Nishimura, H; Odaka, H; Son, C; Yamori, Y; Yoshimasa, Y | 1 |
| Ikeda, S; Watanabe, T | 1 |
| Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A; Shioduka, K | 1 |
| Baillie, R; Clarke, SD; Sha, X; Thuillier, P | 1 |
| Fujimoto, S; Ikeda, H; Ishida, H; Kajikawa, M; Kato, S; Mizuno, N; Mukai, E; Nishimura, M; Odaka, H; Seino, Y; Yamada, Y | 1 |
| Hara, M; Hashimoto, N; Hashimoto, Y; Isoo, N; Kimura, S; Maekawa, H; Satoh, H; Togo, M; Tsukamoto, K; Watanabe, T | 1 |
| Matsui, K; Nagao, K; Shibata, T; Shinkai, H; Wakitani, K; Yonemori, F | 1 |
| Awano, K; Kinoshita, S; Maeda, T; Miyachi, H; Murakami, K; Nomura, M; Satoh, H; Tsunoda, M | 1 |
| Kadowaki, T | 4 |
| Endo, Y; Fujita, T; Kato, K; Midorikawa, S; Mizuno, K; Sato, W; Satoh, H; Tsukamoto, K; Watanabe, T; Yamada, D | 1 |
| Issad, T; Siquier, K; Strobel, A; Strosberg, AD; Zilberfarb, V | 1 |
| Matsui, K; Shibata, T; Wakitani, K; Yonemori, F | 1 |
| Ando, H; Kobayashi, K; Nagai, Y; Nohara, E; Takamura, T; Yamashita, H | 1 |
| Aoki, K; Hirokawa, J; Honda, T; Kawakami, Y; Nishihira, J; Sakaue, S; Tagami, S; Yoshimura, H | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Tang, Y | 1 |
| Henney, JE | 1 |
| Demura, H; Irie, K; Muraki, T; Naruse, K; Naruse, M; Shizume, H; Tago, K; Tanabe, A; Tanaka, M; Yoshimoto, T; Zardi, L | 1 |
| Miller, JL | 1 |
| Asano, M; Chisaki, K; Imuta, H; Iwasawa, K; Morita, T; Nakajima, T; Nakamura, F; Okuda, Y; Omata, M; Yamada, N | 1 |
| Gonoi, T; Inagaki, N; Ishida, H; Seino, S; Seino, Y; Sunaga, Y; Yamada, Y | 1 |
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Aizawa, S; Eto, K; Ezaki, O; Fujita, T; Hasegawa, G; Ishii, C; Kadowaki, T; Kitamura, T; Komeda, K; Kubota, N; Miki, H; Murakami, K; Naito, M; Nakano, R; Okuno, A; Satoh, S; Sekihara, H; Shiota, K; Sugiyama, T; Tamemoto, H; Tanaka, S; Terauchi, Y; Toyoshima, Y; Tsubamoto, Y; Yamauchi, T | 1 |
| Paul, M | 1 |
| Cook, JA; Gilkeson, GS; Halushka, PV; Morrow, JD; Oates, JC; Reilly, CM | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Nakajima, M; Shimada, N; Suzuki, M; Tane, K; Yamazaki, H; Yokoi, T | 1 |
| Ikeda, H; Murase, K; Sugiyama, Y | 1 |
| Shimizu, N | 1 |
| Haruta, T; Iwata, M; Kobayashi, M | 1 |
| Kataoka, K; Oguma, Y | 1 |
| Hirayama, R; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A | 1 |
| Daimon, M; Kato, T; Kimura, M; Manaka, H; Sasaki, H; Tominaga, M | 1 |
| Fukumoto, S; Hosoi, M; Koyama, H; Morii, H; Nishizawa, Y; Tanaka, S; Yamakawa, K | 1 |
| Brown, MN | 1 |
| Gonzalez, R; Grinsell, JW; Lardinois, CK; Michaels, JR; Sare, JS; Starich, GH; Swislocki, A | 1 |
| Chen, Y; Göke, A; Göke, B; Göke, R | 1 |
| King, AB | 1 |
| Reddy, SS | 1 |
| Haneda, M; Isshiki, K; Kikkawa, R; Koya, D; Maeda, S; Sugimoto, T | 1 |
| Chickering, TW; Dussault, B; Friedman, JM; Holmes, WE; Qin, Y; Rosen, ED; Soukas, A; Spiegelman, BM; Yoon, JC | 1 |
| DeFronzo, RA | 1 |
| Krische, D | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Kitahara, M; Naitoh, T; Tsuruzoe, N | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Baum, U | 1 |
| Ludvik, B | 1 |
| Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM | 1 |
| Dunn, CJ; Gillies, PS | 1 |
| Gonzales, N; Nadler, JL; Natarajan, R; Rahbar, S; Scott, S; Yerneni, K | 1 |
| Naruse, M; Tago, K; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T | 1 |
| Stiefelhagen, P | 1 |
| Filz, HP | 1 |
| Hiwada, K; Kitami, Y; Nakamura, M; Okura, T; Takata, Y; Watanabe, S | 1 |
| Banba, N; Hattori, Y; Hishinuma, A; Kakishita, H; Kasai, K; Matsumura, M; Motohashi, S; Sato, N | 1 |
| Argentieri, G; Burkey, BF; Chen, W; de Souza, CJ; Dong, M; Dragonas, N; Eckhardt, M; Gagen, K; Grosenstein, P | 1 |
| Aronoff, S; Braithwaite, S; Egan, JW; Mathisen, AL; Rosenblatt, S; Schneider, RL | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Hirosumi, J; Kojo, H; Mutoh, S; Notsu, Y; Suzuki, A; Yasuno, T | 1 |
| Blumenthal, RS; Nass, CM | 1 |
| Gogg, S; Johansson, A; Olausson, T; Rotter, V; Smith, U; Svalstedt, B | 1 |
| Cheatham, WW; Glazer, NB | 2 |
| Benbow, A; Stewart, M; Yeoman, G | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Albrektsen, T; Fleckner, J | 1 |
| Egan, JW; Einhorn, D; Mathisen, AL; Rendell, M; Rosenzweig, J; Schneider, RL | 1 |
| Blackburn, G | 1 |
| Arakawa, Y; Kimoto, K; Nishijima, C | 1 |
| Abe, T; Nagai, Y; Nomura, G | 1 |
| Lawrence, JM; Reckless, JP | 2 |
| Ebeling, P; Koistinen, HA; Koivisto, VA; Teppo, AM | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Arlt, W; Auchus, RJ; Miller, WL | 1 |
| Peters, AL | 1 |
| Cusi, K; DeFronzo, RA; Ferrannini, E; Glass, L; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y | 1 |
| Ito, T; Morita, H; Nakamura, H; Ohishi, H; Oki, Y; Suzuki, S | 1 |
| Janka, HU | 1 |
| Haruta, T; Ishibashi, O; Iwata, M; Kawahara, J; Kobayashi, M; Sasaoka, T; Takano, A; Takata, Y; Ueno, E; Uno, T; Usui, I | 1 |
| Baba, T; Hashimoto, S; Neugebauer, S; Shimada, K; Watanabe, T; Yamada, D | 1 |
| Koshiyama, H; Kuwamura, N; Nakamura, Y; Shimono, D | 1 |
| Amin, RD; Dilzer, S; Gagliano, K; Kuznetsova, O; Lasseter, KC; Liu, L; Musser, B; Prueksaritanont, T; Roadcap, BA; Rogers, JD; Vega, JM; Zhao, J | 1 |
| Coxon, P; Downes, CP; Macphee, CH; Pass, I; Patel, L; Smith, SA | 1 |
| Matsuyama, K; Naito, Y; Takagi, T; Yoshida, N; Yoshikawa, T | 1 |
| Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A | 1 |
| Gale, EA | 1 |
| Ikeda, H; Sugiyama, Y | 2 |
| Kobayashi, K; Nagai, Y; Nohara, E; Takamura, T | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Koshiyama, H; Kuwamura, N; Minamikawa, J; Nakamura, Y; Shimono, D | 1 |
| Egan, JW; Kipnes, MS; Krosnick, A; Mathisen, AL; Rendell, MS; Schneider, RL | 1 |
| Laws, A | 1 |
| Blicklé, JF | 1 |
| Kanamori, H; Matsuhashi, N; Ohnishi, S; Omata, M; Watanabe, K | 1 |
| Burge, MR; Colleran, K; Sood, V | 1 |
| Aizawa, Y; Hasebe, N; Kawabe , J; Kikuchi, K; Takehara, N | 1 |
| Burkey, BF; Chen, W; de Souza, CJ; Dong, M; Eckhardt, M; Gagen, K; Laurent, D | 1 |
| Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H | 1 |
| Chlenski, A; Hattori, K; Hayashi, Y; Kita, A; Nakashiro, KI; Oyasu, R; Reddy, JK; Tamatani, T; Usuda, N | 1 |
| Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S | 1 |
| Csermely, P; Jermendy, G | 1 |
| Chun, TH; Doi, K; Fukunaga, Y; Hosoda, K; Inoue, M; Itoh, H; Kook, H; Masatsugu, K; Nakao, K; Saito, T; Sawada, N; Tanaka, T; Ueda, M; Yamashita, J | 1 |
| Ando, K; Chiba, Y; Fujita, T; Ogita, T | 1 |
| Maeda, K | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Inoue, K; Kawahito, Y; Kohno, M; Sano, H; Tsubouchi, Y; Yoshikawa, T; Yoshimura, R | 1 |
| Haneda, M; Kikkawa, R; Koya, D | 1 |
| Hara, M; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Smith, U | 1 |
| Hanefeld, M | 1 |
| Belcher, G; Hanefeld, M | 1 |
| Brunetti, P | 1 |
| Birkeland, KI | 1 |
| Chen, Y; El-Deiry, WS; Göke, A; Göke, B; Göke, R | 1 |
| Ichiki, T; Iino, N; Takeda, K; Takeshita, A; Tokunou, T | 1 |
| Chilcott, J; Lloyd Jones, M; Tappenden, P; Wight, J | 1 |
| Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Tsuji, T | 1 |
| Toyota, T | 2 |
| Iwata, M; Kobayashi, M | 1 |
| Kitamura, R; Tanaka, Y | 1 |
| Pospísilová, Y | 1 |
| Quesada-Gómez, JM; Serrano-Alferez, I | 1 |
| Scheen, AJ | 1 |
| Hsueh, WA; Law, RE | 1 |
| Chilcott, J; Jones, ML; Tappenden, P; Wight, JP | 1 |
| Ebihara, I; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T | 1 |
| Hübner, R; Lübben, G | 1 |
| Langan, AS; Vorce, RL; Wauson, EM | 1 |
| Hashimoto, Y; Nakahara, K | 1 |
| Jensen, MD; Shadid, S | 1 |
| Wooltorton, E | 1 |
| Enomoto, N; Hirose, M; Ikejima, K; Kitamura, T; Kon, K; Sato, N; Takei, Y; Yoshikawa, M | 1 |
| Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
| Lotz, N | 1 |
| Chase, MP; Yarze, JC | 1 |
| DeFronzo, RA; Matsuda, M; Miyazaki, Y | 1 |
| Hirose, H; Ishii, T; Kawai, T; Matsubara, K; Oguma, Y; Okazaki, Y; Saruta, T; Takei, I; Taniyama, M; Tomita, M; Yamamoto, Y | 1 |
| Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H | 1 |
| Baba, S | 1 |
| Kram, MT; Lefkowitch, JH; May, LD; Rubin, DE | 1 |
| Nierenberg, DW | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J | 1 |
| Abe, T; Ishibashi, S; Ishikawa, S; Kawakami, A; Kusaka, I; Nagasaka, S; Nakamura, T; Saito, T | 1 |
| Funakoshi, A; Ichikawa, M; Ichimaru, Y; Kanai, S; Kobayash, M; Miyasak, K; Ohta, M; Shimazoe, T; Watanabe, S; Yoshida, Y | 1 |
| Boyle, PJ; King, AB; Lau, H; Magar, R; Marchetti, A; Martin, J; Olansky, L | 1 |
| Furumatsu, T; Inoue, H; Kawai, A; Kunisada, T; Nishida, K; Takada, I; Yoshida, A | 1 |
| Tan, MH | 2 |
| Ikeda, H; Odaka, H; Sugiyama, Y; Suzuki, M; Suzuki, N | 1 |
| Greenberg, AS; Pittas, AG | 1 |
| Amiri, F; Cohn, JS; Diep, QN; El Mabrouk, M; Endemann, D; Neves, MF; Schiffrin, EL; Virdis, A | 1 |
| Grossman, LD | 1 |
| Coyle, D; Lee, KM; O'Brien, BJ | 1 |
| Coyle, D; Palmer, AJ; Tam, R | 1 |
| Henriksson, F | 1 |
| O'Moore-Sullivan, TM; Prins, JB | 1 |
| Iida, KT; Kawakami, Y; Okuda, Y; Shimano, H; Sone, H; Suzuki, H; Toyoshima, H; Yamada, N | 1 |
| Cusi, K; DeFronzo, RA; Hardies, J; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y | 1 |
| Casini, A; Ceni, E; Crabb, DW; Galli, A; Mello, T; Ridolfi, F; Salzano, R; Surrenti, C; Svegliati-Baroni, G; Trozzi, L | 1 |
| Verspohl, EJ; Weiland, F | 1 |
| Einhorn, D; Glazer, NB; Hershon, K; Rosenstock, J; Yu, S | 1 |
| Armstrong, DU; King, AB | 1 |
| Kane, JP | 1 |
| Demcáková, E; Klimes, I; Koranyi, L; Kürthy, M; Mogyorosi, T; Nagy, K; Seböková, E; Ukropec, J | 1 |
| Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L | 1 |
| Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS | 1 |
| Om Reddy, G; Radhakrishna, T; Sreenivas Rao, D | 1 |
| Aiba, A; Harris, PC; Higashihara, E; Horie, S; Katsuki, M; Kitamura, T; Kurabayashi, M; Muto, S; Nagai, R; Nakamura, K; Nakao, K; Saito, Y; Tomita, K | 1 |
| Brosnan, CF; Dumitrescu-Ozimek, L; Feinstein, DL; Galea, E; Gavrilyuk, V; Heneka, MT; Landreth, GE; Pershadsingh, HA; Weinberg, G; Whitacre, CC | 1 |
| Gao, X; Gao, Y; Jia, P; Li, G; Lin, H; Luo, B; Pan, C; Shi, H; Tian, H; Xing, X; Zhao, Y; Zhou, L | 1 |
| Braddon, J; Phillips, P | 1 |
| Breidert, T; Callebert, J; Heneka, MT; Hirsch, EC; Landreth, G; Launay, JM | 1 |
| Ito, T; Matsui, H; Nishimoto, Y; Okumura, K; Tomida, T | 1 |
| Häring, HU; Stumvoll, M | 1 |
| Fudaka, K; Kajio, H; Kanazawa, Y; Kasono, K; Kawakami, M; Masatoshi, K; Namai, K; Nishida, J; Tamemoto, H | 1 |
| Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I | 1 |
| Kubo, K | 1 |
| Hase, T; Kawahito, Y; Mitsuhashi, M; Nakatani, T; Sano, H; Segawa, Y; Wada, S; Yoshimura, R | 1 |
| Abumrad, NA; Kazdova, L; Kren, V; Kurtz, TW; Landa, V; Lezin, ES; Pershadsingh, HA; Pravenec, M; Qi, N; Zidek, V | 1 |
| Mori, Y; Sekihara, H | 1 |
| Yamanouchi, T | 1 |
| Sugiyama, Y | 1 |
| Hiratani, K; Iwata, M; Kobayashi, M | 1 |
| Hosaka, D; Imai, Y; Kawazu, S; Ohmura, E | 1 |
| Bradley, C | 1 |
| Egashira, K; Hiasa, K; Ichiki, T; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Göke, B; Parhofer, KG | 1 |
| Kotake, H | 1 |
| Chalasani, N; Cummings, OW; Pinto, AG | 1 |
| Göke, B; Scherbaum, WA | 1 |
| Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T | 1 |
| LaCivita, KA; Villarreal, G | 1 |
| Cooney, GJ; Dzamko, N; Ellis, B; Frangioudakis, G; Furler, SM; Iglesias, MA; Kraegen, EW; Ye, JM | 1 |
| Anderson, GD; Clarke, A; Edwards, DJ; Jaber, LA; Nowak, SN | 1 |
| Badenhoop, K; Füllert, S; Haak, E; Konrad, T; Lübben, G; Rau, H; Schneider, F; Usadel, KH | 1 |
| Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J | 1 |
| Aburatani, H; Blumberg, RS; Kadowaki, T; Matsuhashi, N; Nagai, R; Nakajima, A; Saubermann, LJ; Terauchi, Y; Wada, K; Zhao, S | 1 |
| Mizushige, K; Noma, T; Tsuji, T | 1 |
| Almeida, A; Bolanos, JP; Dello Russo, C; Feinstein, DL; Galea, E; Gavrilyuk, V; Palmer, J; Pelligrino, D; Weinberg, G | 1 |
| Armstrong, DU; Chinnapongse, S; King, AB | 1 |
| Duvanel, CB; Feinstein, D; Honegger, P; Matthieu, JM; Pershadsingh, H | 1 |
| Awata, T; Inukai, K; Katagiri, H; Katayama, S; Oka, Y; Watanabe, M | 1 |
| Dey, CS; Kumar, N | 1 |
| Baker, G; Davies, S; Evans, M; Heufelder, A; Joba, W; Ludgate, M; Starkey, K | 1 |
| Kaplowitz, N; Lewis, JH; Watkins, PB | 1 |
| Hayashi, Y; Imaeda, K; Itoh, M; Kamiya, F; Kato, T; Miyachi, N; Okayama, N; Shimizu, M; Takeuchi, T; Takeuchi, Y | 1 |
| Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K | 1 |
| Fujisawa, N; Ishimine, S; Kadowaki, T; Kawamori, T; Matsuhashi, N; Nakagama, H; Nakajima, A; Ochiai, M; Osawa, E; Sekihara, H; Wada, K | 1 |
| Iida, KT; Iwama, Y; Kamata, K; Kawakami, Y; Mokuno, H; Shimada, K; Shimano, H; Sone, H; Suzuki, M; Toyoshima, H; Watanabe, Y; Yamada, N | 1 |
| Elmlinger, MW; Plikat, K; Reichle, A; Schölmerich, J | 1 |
| Apolito, RA | 1 |
| Blüher, M; Lübben, G; Paschke, R | 1 |
| Ishii, H; Kanehara, H; Miyamori, I; Oida, K; Suzuki, J; Tohda, G | 1 |
| Hassler, D | 1 |
| Gong, WC; Jun, JK; Mathur, R | 1 |
| Antoine, B; Beale, EG; Chauvet, G; Forest, C; Quette, J; Tordjman, J | 1 |
| Calmy, A; Hans, D; Hirschel, B; Karsegard, VL; Meier, CA | 1 |
| Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Tsuji, T | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Hattori, Y; Kasai, K; Matsumura, M | 1 |
| Fujita, H; Hirose, H; Kawai, T; Miyashita, K; Ogawa, T; Saruta, T; Seto, Y; Ukeda, K; Yajima, K; Yamada, T; Yamamoto, Y | 1 |
| Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT | 1 |
| Budde, K; Eckland, D; Fritsche, L; Neumayer, HH; Stompôr, T; Sulowicz, W | 1 |
| Handa, O; Ichikawa, H; Naito, Y; Takagi, T; Tomatsuri, N; Yoshida, N; Yoshikawa, T | 1 |
| Handa, O; Ichikawa, H; Imamoto, E; Kokura, S; Naito, Y; Takagi, T; Tomatsuri, N; Uchiyama, K; Yoshida, N; Yoshikawa, T | 1 |
| Ichikawa, H; Naito, Y; Takagi, T; Tomatsuri, N; Yoshida, N; Yoshikawa, T | 1 |
| Eguchi, T; Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Shishido, S; Tanaka, E; Ueno, T | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 1 |
| Brass, LM; Bravata, DM; Horwitz, RI; Inzucchi, SE; Kernan, WN; McVeety, JC; Shulman, GI; Viscoli, CM | 1 |
| Adachi, M; Ebara, T; Hirano, T; Kageyama, A; Kageyama, H; Murakami, T; Okada, K; Shioda, S | 1 |
| Bruemmer, D; de Dios, ST; Dilley, RJ; Ivey, ME; Jennings, GL; Law, RE; Little, PJ | 1 |
| Anjaneyulu, M; Ramarao, P | 1 |
| Osawa, K; Ota, T | 1 |
| Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Pratipanawatr, T; Pratipanawatr, W; Suraamornkul, S | 1 |
| Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL | 1 |
| Bazela, K; Brzozowski, T; Hahn, EG; Harsch, I; Kania, J; Konturek, PC; Konturek, SJ; Kukharsky, V; Kwiecien, S | 1 |
| Enomoto, N; Hirose, M; Kitamura, KI; Konno, A; Matsuyama, S; Sato, N; Shibuya, T; Suzuki, S; Takei, Y | 1 |
| Duran, S; Escobar-Jiménez, F; Godin, C; Grossman, LD; Hardin, PA; Hawkins, F; Herz, M; Johns, D; Konkoy, CS; Lochnan, H; Reviriego, J; Tan, MH | 1 |
| Ishida, H; Ito, E; Kikuta, T; Nagamatsu, S; Nakamichi, Y; Nishiwaki, C; Ohara-Imaizumi, M | 1 |
| Diamant, M; Heine, RJ | 1 |
| Odaka, H; Suzuki, M | 1 |
| Chandramouli, J; Tolman, KG | 1 |
| Ibuki, M; Katayama, M; Mizoguchi, S; Morioka, S; Nagai, K; Shiratori, K; Takagi, T; Tamita, K; Tanabe, K; Tani, T; Yamabe, K; Yamamuro, A; Yoshikawa, J | 1 |
| Ito, S; Ogawa, S; Takeuchi, K | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Babu-Khan, S; Biere, AL; Citron, M; Landreth, G; Liu, H; Vassar, R; Yan, Q; Zhang, J | 1 |
| Buse, JB | 1 |
| Jensen, PB; Larsen, LK; Larsen, PJ; Sørensen, RV; Vrang, N; Wassermann, K; Wulff, EM | 1 |
| Bach, H; Grüb, M; Hetzel, M; Hombach, V; Marx, N; Walcher, D | 1 |
| Bujo, H; Itou, T; Saito, Y; Shibasaki, M; Takahashi, K | 1 |
| Narce, M; Poisson, JP | 1 |
| Thiemermann, C | 1 |
| Berger, JP; Biswas, C; Chao, YS; Doebber, TW; Ippolito, MC; Kelly, LJ; Li, Y; Meurer, R; Moller, DE; Wang, PR; Wright, SD; Wu, MS; Zhou, G | 1 |
| Fujimoto, M; Hayashi, T; Hosoda, K; Inoue, G; Masuzaki, H; Muraoka, S; Nakao, K; Norisada, N; Watanabe, M; Yoneda, F | 1 |
| Cha, JY; Ge, H; Gopal, H; Harp, C; Li, C; Repa, JJ; Yu, X | 1 |
| DI, WJ; Ding, GX; Liu, J; Xie, Y; Yu, J; Zha, JM; Zhong, Y; Zhu, T | 1 |
| Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
| Heneka, MT; Hermes, M; Kummer, MP; Orlandi, M; Papi, A; Tatenhorst, L; Terwel, D | 1 |
| Karpushev, AV; Levchenko, V; Pavlov, TS; Staruschenko, A; Vandewalle, A | 1 |
| Boullerne, AI; Feinstein, DL; Peters, JM; Polak, PE; Richardson, JC; Vittoria Simonini, M | 1 |
| Agrawal, RK; Jain, AK; Kashaw, SK; Ravichandran, V; Vaidya, A | 1 |
| Camussi, G; Fantozzi, R; Grange, C; Miglio, G; Rattazzi, L; Rosa, AC | 1 |
| Ito, H; Kohno, K; Miyoshi, T; Morita, H; Nakamura, K; Noda, Y; Oe, H; Ohno, Y; Osawa, K; Saito, Y; Sakatani, Y | 1 |
| Benavidez, JM; Black, M; Blednov, YA; Edenberg, HJ; Ferguson, LB; Foroud, T; Goate, AM; Harris, RA; Hesselbrock, V; Schoenhard, GL; Wetherill, L | 1 |
| Goduni, E; Jay, T; Lamb, BT; Landreth, GE; Malm, T; Mariani, MM; Quigley, C; Ransohoff, RM; Savage, JC | 1 |
| Ding, H; Landry, AP; Wang, Y | 1 |
| Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY | 1 |
| Chen, J; Confides, AL; Dupont-Versteegden, EE; El Khouli, RH; Finlin, BS; Johnson, ZR; Kern, PA; Memetimin, H; Morris, AJ; Sullivan, PG; Vekaria, HJ; Westgate, PM; Zhu, B | 1 |
79 review(s) available for thiazoles and pioglitazone
| Article | Year |
|---|---|
New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pioglitazone; Thiazoles; Thiazolidinediones | 1992 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Mice; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1996 |
[Preclinical studies of pioglitazone (AD-4833)].
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Hypoglycemic Agents; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
[Clinical efficacy of Pioglitazone (AD-4833)].
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Combination therapy of insulin sensitizer and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Protein Precursors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Mechanisms and clinical effects of pioglatizone as a new agent for the treatment of type-2 diabetes].
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Pioglitazone; Thiazoles; Thiazolidinediones | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Clinical evaluation of pioglitazone].
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Obesity, insulin resistance and the implication of thiazolidinediones].
Topics: Adipose Tissue; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptor, Insulin; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2000 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Pioglitazone.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Pioglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Education, Continuing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; United States | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones: a comparative review of approved uses.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gene Expression Regulation; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Actos (pioglitazone): a new treatment for type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Pioglitazone and rosiglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone: mechanism of action.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nuclear Proteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Pharmacokinetics and clinical efficacy of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
Safety profile of pioglitazone.
Topics: Cardiovascular System; Edema; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Weight Gain | 2001 |
Pioglitazone: the future.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Forecasting; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
[A trend of insulin sensitizer which is under development].
Topics: Animals; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Pharmacological effects of a thiazolidinedione derivative, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Clinical usefulness of combination treatment with thiazolidinedione and insulin].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Multicenter Studies as Topic; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[News in oral antidiabetic therapy].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
Pioglitazone: a review of Japanese clinical studies.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypoglycemic Agents; Japan; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Current treatment of insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Thiazolidinediones in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
New solutions for type 2 diabetes mellitus: the role of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Absorption; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2002 |
The role of models within economic analysis: focus on type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.
Topics: Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Health Care Sector; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Prevalence; Sweden; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinediones and type 2 diabetes: new drugs for an old disease.
Topics: Adult; Aged; Australia; Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Against insulin resistance. Insulin sensitizers].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Adverse effects of oral hypoglycemic agents].
Topics: Acarbose; Administration, Oral; Biguanides; Cyclohexanes; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Nateglinide; Phenylalanine; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipid Metabolism; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Glitazone--a new drug for type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Perspective for development of insulin sensitizers].
Topics: Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
The glitazones: a new treatment for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone: cardiovascular effects in prediabetic patients.
Topics: Animals; Aorta; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hypoglycemic Agents; Muscle, Smooth, Vascular; Myocardium; Pioglitazone; Prediabetic State; Thiazoles; Thiazolidinediones | 2002 |
[Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
Topics: Cardiovascular Diseases; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Pioglitazone; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2003 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Recent developments and biological activities of thiazolidinone derivatives: a review.
Topics: Analgesics; Anti-Bacterial Agents; Anticonvulsants; Antidepressive Agents; Antifungal Agents; Antihypertensive Agents; Antineoplastic Agents; Antitubercular Agents; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Receptor, Muscarinic M1; Streptomyces; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 2012 |
32 trial(s) available for thiazoles and pioglitazone
| Article | Year |
|---|---|
High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Hydrolysis; Hypoglycemic Agents; Indicators and Reagents; Pioglitazone; Reproducibility of Results; Thiazoles; Thiazolidinediones | 1996 |
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1998 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebos; Racial Groups; Thiazoles; Thiazolidinediones; United States | 2000 |
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazoles; Thiazolidinediones | 2000 |
Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes.
Topics: Acute-Phase Proteins; Blood Glucose; Blood Proteins; C-Reactive Protein; Complement Activation; Complement C3; Complement C3a; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osmolar Concentration; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Middle Aged; Pioglitazone; Placebos; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Humans; Hypoglycemic Agents; Lymphokines; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Chromans; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Female; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
Topics: Arteriosclerosis; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; United States | 2001 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Lipoproteins; Male; Middle Aged; Pioglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2001 |
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.
Topics: Albuminuria; Blood Glucose; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Pioglitazone; Renal Dialysis; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Ethnicity; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
[The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
Topics: Blood Pressure; Body Weight; Cholesterol; Consumer Product Safety; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Topics: Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Double-Blind Method; Fasting; Female; Homeostasis; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Placebos; Thiazoles; Thiazolidinediones | 2002 |
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2003 |
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2003 |
Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Hispanic or Latino; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; United States | 2003 |
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
Topics: Adult; Anthropometry; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Prospective Studies; Thiazoles; Thiazolidinediones | 2003 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
The pharmacokinetics of pioglitazone in patients with impaired renal function.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Female; Half-Life; Humans; Hypoglycemic Agents; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2003 |
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
Topics: Aged; Blood Glucose; Brain Ischemia; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ischemic Attack, Transient; Male; Patient Compliance; Pioglitazone; Risk Factors; Stroke; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; Coronary Angiography; Coronary Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Stents; Thiazoles; Thiazolidinediones; Tunica Intima; Ultrasonography, Interventional | 2003 |
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.
Topics: Aged; Atrial Natriuretic Factor; Body Mass Index; Buformin; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Natriuretic Peptide, Brain; Pioglitazone; Stroke Volume; Thiazoles; Thiazolidinediones | 2003 |
Pioglitazone prevents the endothelial dysfunction induced by ischemia and reperfusion in healthy subjects.
Topics: Adult; Blood Flow Velocity; Brachial Artery; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Female; Healthy Volunteers; Humans; Male; Meloxicam; Pioglitazone; PPAR gamma; Reperfusion Injury; Superoxide Dismutase; Thiazines; Thiazoles; Thiazolidinediones; Vasodilation | 2014 |
289 other study(ies) available for thiazoles and pioglitazone
| Article | Year |
|---|---|
Pioglitazone increases insulin sensitivity by activating insulin receptor kinase.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Phosphorylation; Pioglitazone; Protein-Tyrosine Kinases; Rats; Rats, Inbred Strains; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1992 |
Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent.
Topics: 3T3 Cells; Adipose Tissue; Animals; Carrier Proteins; Dexamethasone; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Obese; Neoplasm Proteins; Nerve Tissue Proteins; Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones | 1992 |
Enhancement of adipocyte differentiation by an insulin-sensitizing agent.
Topics: 3T3 Cells; Adipose Tissue; Animals; Cell Differentiation; Cells, Cultured; Glucosephosphate Dehydrogenase; Hypoglycemic Agents; Insulin; Insulin-Like Growth Factor I; Lipids; Lipoprotein Lipase; Mice; Monosaccharide Transport Proteins; Phenotype; Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides | 1992 |
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Mice; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1992 |
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
Topics: Animals; Crosses, Genetic; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Monosaccharide Transport Proteins; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones | 1992 |
Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin; Intestinal Absorption; Intestinal Mucosa; Male; Microsomes; NADH Dehydrogenase; Pioglitazone; Rats; Rats, Inbred Strains; Reference Values; Sterol O-Acyltransferase; Thiazoles; Thiazolidinediones | 1991 |
Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.
Topics: Administration, Oral; Animals; Biological Transport; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1991 |
Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Mice, Obese; Molecular Conformation; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1991 |
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Muscles; Obesity; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1990 |
Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Topics: Animals; Blood Glucose; Body Weight; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones; Triglycerides | 1990 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred Strains; Mice, Obese; Pioglitazone; Rats; Rats, Inbred Strains; Rats, Zucker; Species Specificity; Thiazoles; Thiazolidinediones | 1990 |
Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones.
Topics: Animals; Chemical Phenomena; Chemistry; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Mice; Mice, Inbred Strains; Mice, Obese; Pioglitazone; Pyridines; Thiazoles; Thiazolidinediones; Triglycerides | 1990 |
Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detection.
Topics: Animals; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Dogs; Hypoglycemic Agents; Pioglitazone; Spectrophotometry, Ultraviolet; Thiazoles; Thiazolidinediones | 1989 |
Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat.
Topics: Acarbose; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fasting; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Obesity; Pioglitazone; Pulsatile Flow; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Trisaccharides; Weaning | 1995 |
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.
Topics: 1-Phosphatidylinositol 4-Kinase; 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cyclic AMP; Enzyme Activation; Hypoglycemic Agents; Immunosorbent Techniques; Insulin; Insulin-Like Growth Factor I; Isoproterenol; Kinetics; Male; Mice; Mice, Inbred C57BL; Phosphotransferases (Alcohol Group Acceptor); Phosphotyrosine; Pioglitazone; Thiazoles; Thiazolidinediones; Tyrosine | 1994 |
Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.
Topics: Aminoisobutyric Acids; Animals; Biological Transport; Blotting, Western; Cell Line; Cytosol; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Kinetics; Macromolecular Substances; Phosphotyrosine; Pioglitazone; Protein Tyrosine Phosphatases; Raffinose; Rats; Receptor, Insulin; Recombinant Proteins; Swine; Thiazoles; Thiazolidinediones; Transfection; Tyrosine | 1995 |
Polyunsaturated fatty acid-mediated suppression of insulin-dependent gene expression of lipogenic enzymes in rat liver.
Topics: Acetyl-CoA Carboxylase; Animals; ATP Citrate (pro-S)-Lyase; Corn Oil; Diabetes Mellitus, Experimental; Fatty Acid Synthases; Fatty Acids, Unsaturated; Gene Expression Regulation, Enzymologic; Glucosephosphate Dehydrogenase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Malate Dehydrogenase; Male; Phosphorylation; Pioglitazone; Rats; Rats, Wistar; Receptor, Insulin; RNA, Messenger; Thiazoles; Thiazolidinediones | 1995 |
Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; In Vitro Techniques; Insulin; Magnesium; Male; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 1995 |
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
Topics: Aging; Amino Acids; Animals; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pioglitazone; Rats; Rats, Zucker; Reference Values; Thiazoles; Thiazolidinediones; Tolbutamide | 1995 |
Pioglitazone attenuates diet-induced hypertension in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diet; Dietary Carbohydrates; Dietary Fats; Hypertension; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 1995 |
Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes.
Topics: Animals; Blood Glucose; Body Weight; Fatty Acids, Nonesterified; Female; Glucose; Insulin; Monosaccharide Transport Proteins; Muscles; Phosphoric Monoester Hydrolases; Pioglitazone; Rats; Rats, Mutant Strains; Sarcolemma; Thiazoles; Thiazolidinediones; Triglycerides | 1995 |
Insulin sensitization in diabetic rat liver by an antihyperglycemic agent.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Gene Expression; Glucokinase; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Thiazolidinediones | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Glucose Clamp Technique; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Pioglitazone; Rats; Rats, Wistar; Streptozocin; Thiazoles; Thiazolidinediones; Troglitazone | 1993 |
Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cyclic AMP; Insulin; Insulin-Like Growth Factor I; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Pioglitazone; Precipitin Tests; Thiazoles; Thiazolidinediones | 1994 |
Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Muscles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pioglitazone; Protein-Tyrosine Kinases; Rats; Receptor, Insulin; Signal Transduction; Thiazoles; Thiazolidinediones | 1994 |
Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.
Topics: Animals; Antihypertensive Agents; Insulin; Male; Metformin; Pioglitazone; Rats; Rats, Sprague-Dawley; Sodium; Thiazoles; Thiazolidinediones | 1994 |
Evidence that pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adipocytes.
Topics: Adipocytes; Adipose Tissue; Animals; Calcium; Cells, Cultured; Dose-Response Relationship, Drug; Epididymis; Fluorescent Dyes; Fura-2; Hypoglycemic Agents; Magnesium; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones | 1994 |
Effects of pioglitazone on calcium channels in vascular smooth muscle.
Topics: Animals; Calcium Channels; Cells, Cultured; Dimethyl Sulfoxide; Hypoglycemic Agents; Male; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 1994 |
Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol.
Topics: Animals; Blood; Diglycerides; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Liver; Male; Malonyl Coenzyme A; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones | 1994 |
Regulation of glucose transport by pioglitazone in cultured muscle cells.
Topics: Analysis of Variance; Animals; Blotting, Northern; Blotting, Western; Cell Line; Deoxyglucose; Dose-Response Relationship, Drug; Glucose Transporter Type 1; Humans; Hypoglycemic Agents; Monosaccharide Transport Proteins; Muscles; Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones | 1994 |
Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Hypoglycemic Agents; Mice; Molecular Sequence Data; Neoplasm Proteins; Nerve Tissue Proteins; Oligodeoxyribonucleotides; Pioglitazone; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Thiazoles; Thiazolidinediones | 1994 |
Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats.
Topics: Animals; Arterioles; Blood Pressure; Cell Division; Epidermal Growth Factor; Hypertension; Hypoglycemic Agents; Insulin; Kidney; Male; Muscle, Smooth; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Sodium Chloride; Thiazoles; Thiazolidinediones; Thymidine | 1993 |
Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscles; Obesity; Pioglitazone; Receptors, Tumor Necrosis Factor; RNA, Messenger; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1994 |
Pioglitazone ameliorates high glucose induced desensitization of insulin receptor kinase in Rat 1 fibroblasts in culture.
Topics: Animals; Cell Line; Enzyme Activation; Fibroblasts; Glucose; Hypoglycemic Agents; Insulin; Kinetics; Phosphorylation; Pioglitazone; Protein-Tyrosine Kinases; Rats; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1993 |
Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Eating; Fasting; Feeding Behavior; Female; Glucose Tolerance Test; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Macaca mulatta; Male; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Tolbutamide; Triglycerides | 1994 |
Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Feeding Behavior; Female; Growth Hormone; Humans; Hypoglycemic Agents; Hypophysectomy; Insulin Resistance; Mice; Mice, Obese; Pioglitazone; Thiazoles; Thiazolidinediones | 1994 |
The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability.
Topics: 3T3 Cells; Adipose Tissue; Animals; Biological Transport; Cell Differentiation; Drug Stability; Gene Expression; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1993 |
Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells.
Topics: 3T3 Cells; Adipose Tissue; Animals; Cell Differentiation; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Pioglitazone; RNA, Messenger; Thiazoles; Thiazolidinediones | 1993 |
Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Muscles; Phosphorylation; Pioglitazone; Precipitin Tests; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1993 |
Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity.
Topics: Animals; Cell Membrane; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phosphoinositide Phospholipase C; Phosphoric Diester Hydrolases; Pioglitazone; Thiazoles; Thiazolidinediones | 1993 |
Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle.
Topics: Animals; Benzopyrans; Blood Glucose; Deoxyglucose; Dexamethasone; Glucocorticoids; Glucose Transporter Type 4; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Isomerism; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscles; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Tritium | 1993 |
Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycoproteins; Hypoglycemic Agents; Lipoproteins; Lipoproteins, HDL; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pioglitazone; Thiazoles; Thiazolidinediones | 1993 |
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Carrier Proteins; Cell Differentiation; Complement Factor D; DNA-Binding Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fibroblasts; Hypoglycemic Agents; Ligands; Mice; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Pioglitazone; Prostaglandin D2; Prostaglandins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Serine Endopeptidases; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 1995 |
Studies on antidiabetic agents. XII. Synthesis and activity of the metabolites of (+/-)-5(-)[p(-)[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4- thiazolidinedione (pioglitazone).
Topics: Animals; Biotransformation; Blood Glucose; Hydroxylation; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Obesity; Pioglitazone; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1995 |
Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Dietary Carbohydrates; Dietary Fats; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Malonyl Coenzyme A; Muscle, Skeletal; Pioglitazone; Rats; Rats, Sprague-Dawley; Sodium Chloride; Thiazoles; Thiazolidinediones; Triglycerides | 1996 |
VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone.
Topics: Animals; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease Models, Animal; Energy Intake; Fatty Acids, Nonesterified; Fructose; Hypoglycemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Thinness; Triglycerides | 1996 |
Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats.
Topics: Animals; Blood Glucose; Body Weight; Gene Expression; Hindlimb; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Male; Muscle, Skeletal; Obesity; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Phosphotyrosine; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Receptor, Insulin; Reference Values; Signal Transduction; Thiazoles; Thiazolidinediones; Triglycerides | 1996 |
Pioglitazone attenuates the inhibitory effect of phorbol ester on epidermal growth factor receptor autophosphorylation and tyrosine kinase activity.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Humans; Hypoglycemic Agents; Phosphorylation; Pioglitazone; Protein Kinase C; Protein Tyrosine Phosphatases; Receptor Protein-Tyrosine Kinases; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured | 1996 |
A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Base Sequence; Benzopyrans; Chromans; DNA, Complementary; Fatty Acids; Humans; Mice; Molecular Sequence Data; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1996 |
Pioglitazone hydrochloride stimulates insulin secretion in HIT-T 15 cells by inducing Ca2+ influx.
Topics: Animals; Calcium; Calcium Channel Blockers; Cell Line; Cricetinae; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nifedipine; Pioglitazone; Stimulation, Chemical; Thiazoles; Thiazolidinediones | 1996 |
Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction.
Topics: Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 1996 |
Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent.
Topics: Adipocytes; Adipose Tissue, Brown; Animals; Blotting, Western; Carrier Proteins; Cell Differentiation; Cells, Cultured; Drug Synergism; Female; Gene Expression Regulation; Hypoglycemic Agents; Ion Channels; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondrial Proteins; Norepinephrine; Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiazoles; Thiazolidinediones; Uncoupling Protein 1 | 1996 |
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Adipose Tissue; Animals; Base Sequence; DNA Primers; Enzyme Activation; Gene Expression; Humans; Leptin; Liver; Molecular Sequence Data; Organ Size; Pioglitazone; Promoter Regions, Genetic; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Effect of pioglitazone on vascular reactivity in vivo and in vitro.
Topics: Animals; Aorta; Cells, Cultured; Glucose; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Vasoconstriction; Vasodilation | 1996 |
Microbiological N-deoxygenation and C-oxygenation of pioglitazone-N-oxide in a single fermentation.
Topics: Fermentation; Hypoglycemic Agents; Pioglitazone; Streptomyces; Thiazoles; Thiazolidinediones | 1996 |
Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.
Topics: Animals; Caprylates; Carnitine O-Palmitoyltransferase; Cells, Cultured; Chromans; Coenzyme A Ligases; Fasting; Gluconeogenesis; Hypoglycemic Agents; Ketone Bodies; Kinetics; Liver; Male; Microsomes, Liver; Oleic Acid; Oxidation-Reduction; Phospholipids; Pioglitazone; Rats; Rats, Wistar; Repressor Proteins; Saccharomyces cerevisiae Proteins; Starvation; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1996 |
Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation.
Topics: Animals; Aorta, Thoracic; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1996 |
Prolactin receptor expression during adipocyte differentiation of bone marrow stroma.
Topics: Adipocytes; Animals; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Mice; Pioglitazone; Receptors, Prolactin; Rosiglitazone; Stem Cells; Stromal Cells; Thiazoles; Thiazolidinediones | 1996 |
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
Topics: Animals; Dogs; Half-Life; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Pioglitazone; Rats; Thiazoles; Thiazolidinediones | 1996 |
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
Topics: Adipocytes; Antigens, Differentiation; Cell Differentiation; Fibroblasts; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 1997 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dogs; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs.
Topics: Administration, Oral; Animals; Bile; Biotransformation; Chromatography, Liquid; Dogs; Hypoglycemic Agents; Intubation, Gastrointestinal; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 1997 |
Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
Topics: Administration, Oral; Animals; Area Under Curve; Biotransformation; Dogs; Half-Life; Hypoglycemic Agents; In Vitro Techniques; Injections, Intravenous; Intestinal Absorption; Macaca fascicularis; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Tissue Distribution | 1997 |
Troglitazone has a scavenging effect on reactive oxygen species.
Topics: Antioxidants; Chromans; Cytochrome c Group; Dimethyl Sulfoxide; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Humans; Hydrogen Peroxide; Iron; Molecular Structure; Neutrophils; Pioglitazone; Reactive Oxygen Species; Spin Labels; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E; Xanthine; Xanthine Oxidase; Xanthines | 1997 |
Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice.
Topics: Animals; Blood Glucose; Body Weight; Carcinoma, Hepatocellular; Cell Division; Diabetes Mellitus, Type 2; DNA; Dose-Response Relationship, Drug; Drug Synergism; Glyburide; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured | 1997 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Epinephrine; Hypertension; Hypoglycemic Agents; Kidney Cortex; Kidney Glomerulus; Male; Norepinephrine; Obesity; Pioglitazone; Proteinuria; Rats; Rats, Inbred WF; Rats, Mutant Strains; Rats, Wistar; Sodium; Thiazoles; Thiazolidinediones; Triglycerides; Tunica Media | 1997 |
Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Catecholamines; Dietary Sucrose; Glucose Tolerance Test; Hexamethonium; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Thiazoles; Thiazolidinediones | 1997 |
PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.
Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Transformed; DNA-Binding Proteins; E2F Transcription Factors; Ligands; Mice; Phosphoprotein Phosphatases; Phosphorylation; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Retinoblastoma-Binding Protein 1; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factor DP1; Transcription Factors | 1997 |
KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production.
Topics: Animals; Blood Glucose; Body Weight; Glycine; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metalloendopeptidases; Mice; Mice, Inbred BALB C; Pioglitazone; Protease Inhibitors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1997 |
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.
Topics: Adipocytes; Animals; Body Weight; Cell Differentiation; Fatty Acid Synthases; Female; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Glucose; Glucose Transporter Type 4; Insulin Resistance; Leptin; Lipid Metabolism; Lipid Mobilization; Monosaccharide Transport Proteins; Muscle Proteins; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Proteins; Rats; Rats, Mutant Strains; Thiazoles; Thiazolidinediones | 1997 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Neoplasms, Experimental; Metformin; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Drinking; Fructose; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Inbred WKY; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 1997 |
Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling.
Topics: 3T3 Cells; Adipocytes; Animals; Chromans; Drug Interactions; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Ligands; Mice; NF-kappa B; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 1997 |
Disparate effects of antidiabetic drugs on arterial contraction.
Topics: Animals; Arteries; Blood Pressure; Glyburide; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Male; Metformin; Muscle Contraction; Muscle, Smooth, Vascular; Pioglitazone; Potassium Chloride; Rats; Rats, Wistar; Tail; Thiazoles; Thiazolidinediones | 1997 |
Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat.
Topics: Acetylcholine; Adipocytes; Animals; Blood Pressure; Fructose; Glucose; Insulin; Insulin Resistance; Male; Norepinephrine; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Vasoconstrictor Agents; Vasodilation | 1997 |
Pioglitazone-reduced insulin resistance in patient with Werner syndrome.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Werner Syndrome | 1997 |
Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization.
Topics: Actins; Animals; Blood Glucose; Carotid Arteries; Catheterization; Cell Count; Cell Division; Cells, Cultured; Female; Hypoglycemic Agents; Insulin; Lipids; Male; Muscle, Smooth, Vascular; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 1997 |
Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Northern; Chromans; DNA Probes; Fatty Acids; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; RNA, Messenger; Stearoyl-CoA Desaturase; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Acute effects of pioglitazone on glucose metabolism in perfused rat liver.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Fructosediphosphates; Glucose; Hypoglycemic Agents; In Vitro Techniques; Liver; Male; Perfusion; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats.
Topics: Animals; Arginine Vasopressin; Drug Evaluation, Preclinical; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin; Male; Norepinephrine; Pioglitazone; Potassium Chloride; Rats; Rats, Inbred SHR; Thiazoles; Thiazolidinediones; Vasodilator Agents | 1998 |
Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Immunoenzyme Techniques; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Sphingomyelin Phosphodiesterase; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
High glucose-induced abnormal epidermal growth factor signaling.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Membrane; Cells, Cultured; Cytosol; Epidermal Growth Factor; Fibroblasts; Glucose; Humans; Hypoglycemic Agents; Isoenzymes; Phosphorylation; Pioglitazone; Protein Tyrosine Phosphatases; Rats; Receptor, Insulin; RNA, Messenger; Signal Transduction; Thiazoles; Thiazolidinediones | 1998 |
Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes.
Topics: Animals; Cells, Cultured; Enzyme Activation; Glycogen Synthase; Hyperglycemia; Hypoglycemic Agents; Insulin; Liver; Male; Phosphoprotein Phosphatases; Pioglitazone; Protein Phosphatase 1; Rats; Thiazoles; Thiazolidinediones; Time Factors | 1998 |
Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro.
Topics: Animals; Cell Division; Chromans; Endothelium, Vascular; Fibroblast Growth Factor 2; Hypoglycemic Agents; Insulin; Mice; Mice, Inbred BALB C; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Topics: Adenosine Diphosphate; Blood Platelets; Blood Proteins; Chromans; Collagen; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphorylation; Pioglitazone; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Thiazoles; Thiazolidinediones; Thrombin; Troglitazone; Vitamin E | 1998 |
Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation.
Topics: Adipocytes; Animals; Cell Differentiation; fas Receptor; Female; Gene Expression; Glucose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Muscle, Skeletal; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Rats; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones | 1998 |
The effect of pioglitazone on glucose metabolism and insulin uptake in the perfused liver and hindquarter of high-fructose-fed rats.
Topics: Animals; Fructose; Glucose; Hypoglycemic Agents; Insulin; Liver; Male; Muscles; Perfusion; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 1998 |
Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
Topics: Animals; Binding Sites; CREB-Binding Protein; Cricetinae; Energy Transfer; Estrogen Receptor alpha; Histone Acetyltransferases; Nuclear Proteins; Nuclear Receptor Coactivator 1; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Rosiglitazone; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 1998 |
A novel 3T3-L1 preadipocyte variant that expresses PPARgamma2 and RXRalpha but does not undergo differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Carrier Proteins; Cell Differentiation; DNA; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Glyceraldehyde-3-Phosphate Dehydrogenases; Hypoglycemic Agents; Mice; Mutation; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Injections, Subcutaneous; Ion Channels; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mitochondrial Proteins; Muscle, Skeletal; Pioglitazone; Proteins; RNA, Messenger; Thiazoles; Thiazolidinediones; Uncoupling Agents; Uncoupling Protein 2; Uncoupling Protein 3 | 1998 |
Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, Brown; Animals; Carrier Proteins; Cells, Cultured; Energy Metabolism; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Ion Channels; Male; Membrane Transport Proteins; Mitochondrial Proteins; Muscle, Skeletal; Pioglitazone; Proteins; Rats; Rats, Sprague-Dawley; Rats, Wistar; RNA, Messenger; Thiazoles; Thiazolidinediones; Uncoupling Protein 2; Uncoupling Protein 3 | 1998 |
Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes.
Topics: Action Potentials; Animals; Chromans; Heart Ventricles; In Vitro Techniques; Male; Membrane Potentials; Pioglitazone; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Biological Transport; Carrier Proteins; Cell Differentiation; Deoxyglucose; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Genes, Reporter; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Inositol 1,4,5-Trisphosphate; Insulin; Mice; Monocytes; Monosaccharide Transport Proteins; Muscle Proteins; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Phosphatidylinositol 3-Kinases; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1998 |
Cytosolic and nuclear distribution of PPARgamma2 in differentiating 3T3-L1 preadipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cytosol; Mice; Nuclear Proteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Response Elements; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Triglycerides | 1998 |
Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.
Topics: Animals; Cattle; Cells, Cultured; Chromans; Endothelin-1; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Isoxazoles; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1999 |
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
Topics: Animals; Blood Glucose; Hypoglycemic Agents; Insulin; Mice; Mice, Obese; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Thiazolidines; Triglycerides | 1999 |
Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.
Topics: Base Sequence; Cells, Cultured; Chromans; DNA Primers; Down-Regulation; Endothelium, Vascular; Humans; Pioglitazone; Plasminogen Activator Inhibitor 1; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 1999 |
Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes.
Topics: Adipocytes; Biomarkers; Cell Differentiation; Cell Line, Transformed; Gene Expression; Humans; Hypoglycemic Agents; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Pioglitazone; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Thiazolidinediones; Triglycerides; Uncoupling Protein 2 | 1999 |
Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Isoxazoles; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Triglycerides | 1999 |
Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypoglycemic Agents; Islets of Langerhans; Male; Mice; Pioglitazone; Streptozocin; Thiazoles; Thiazolidinediones; Time Factors | 1999 |
Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro.
Topics: 3T3 Cells; Adipose Tissue; Animals; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Insulin; Macrophage Migration-Inhibitory Factors; Male; Mice; Pioglitazone; Rats; Rats, Long-Evans; Rats, Wistar; Thiazoles; Thiazolidinediones | 1999 |
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1999 |
From the Food and Drug Administration.
Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA; Fibronectins; Hypertension; Hypertrophy; Hypoglycemic Agents; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Pioglitazone; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Thiazoles; Thiazolidinediones; Tunica Intima | 1999 |
FDA approves pioglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
Topics: Animals; Calcium; Calcium Channels, L-Type; Cell Division; Cell Line; Chromans; Hypoglycemic Agents; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Platelet-Derived Growth Factor; Prostaglandin D2; Rats; Thiazoles; Thiazolidinediones; Troglitazone; Vasopressins | 1999 |
Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Chromans; COS Cells; Diazoxide; Electrophysiology; Glyburide; Membrane Potentials; Pinacidil; Pioglitazone; Potassium Channels; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Recombinant Fusion Proteins; Rubidium Radioisotopes; Sulfonylurea Receptors; Thiazoles; Thiazolidinediones; Transfection; Troglitazone | 1999 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cell Differentiation; Cell Size; Diet; Eating; Energy Metabolism; Fats; Fetal Viability; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Myocardium; Pioglitazone; Placenta; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Female; Glomerular Mesangium; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxisomes; Pioglitazone; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Topics: Chromans; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Oxidation-Reduction; Pioglitazone; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Xenobiotics | 2000 |
New drug overview. Pioglitazone hydrochloride.
Topics: Animals; Diabetes Mellitus; Drug Interactions; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Oxadiazoles; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Weight Gain | 2000 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Technique; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells.
Topics: Acetophenones; Cells, Cultured; Chromans; Endothelial Growth Factors; Gene Expression Regulation; Humans; Lymphokines; Muscle, Smooth, Vascular; Peroxisome Proliferators; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents | 2000 |
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Area Under Curve; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucose; Hyperglycemia; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Postprandial Period; Rats; Rats, Inbred SHR; Thiazoles; Thiazolidinediones | 2000 |
Regulation of TRAIL-induced apoptosis by transcription factors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Humans; Jurkat Cells; Membrane Glycoproteins; NF-kappa B; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Sulfasalazine; Thiazoles; Thiazolidinediones; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Diglycerides; Extracellular Matrix Proteins; Hemodynamics; Insulin; Kidney Glomerulus; Male; Mitogen-Activated Protein Kinases; Pioglitazone; Protein Kinase C; Rats; Rats, Sprague-Dawley; Renal Circulation; RNA, Messenger; Thiazoles; Thiazolidinediones; Transforming Growth Factor beta; Troglitazone | 2000 |
Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation.
Topics: 3T3 Cells; Adipose Tissue; Amino Acid Sequence; Angiopoietin-Like Protein 2; Angiopoietin-Like Protein 4; Angiopoietin-like Proteins; Angiopoietins; Animals; Base Sequence; Blood Proteins; Cell Differentiation; Cycloheximide; Female; Gene Expression Regulation; Glycoproteins; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Leptin; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Sequence Data; Muscle Proteins; Nutritional Physiological Phenomena; Pioglitazone; Placenta; Pregnancy; Receptors, Cytoplasmic and Nuclear; Sequence Homology, Amino Acid; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1.
Topics: Antineoplastic Agents; Carcinogens; Cell Survival; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Ligands; Monocytes; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
[Thiazolidinediones in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Information on thiazolidinediones.
Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
Pioglitazone (Actos).
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Function Tests; Pioglitazone; Thiazoles; Thiazolidinediones | 1999 |
Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation.
Topics: Enzyme-Linked Immunosorbent Assay; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Metformin; Pentoxifylline; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Chromans; GADD45 Proteins; Gene Expression; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Pioglitazone; Platelet Aggregation Inhibitors; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Suppressor Protein p53 | 2000 |
15-Deoxy-Delta(12,14)-prostaglandin J(2) facilitates thyroglobulin production by cultured human thyrocytes.
Topics: Anticholesteremic Agents; Arsenites; Bucladesine; Cells, Cultured; Chromans; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fetal Proteins; Gene Expression Regulation, Enzymologic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Hypoglycemic Agents; Ligands; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pioglitazone; Prostaglandin D2; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Sodium Compounds; Thiazoles; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyrotropin; Transcription Factors; Troglitazone | 2000 |
Effects of pioglitazone on promoting energy storage, not expenditure, in brown adipose tissue of obese fa/fa Zucker rats: comparison to CL 316,243.
Topics: Adipose Tissue, Brown; Animals; Carrier Proteins; Dioxoles; DNA; Energy Metabolism; Female; Hypoglycemic Agents; Ion Channels; Membrane Proteins; Mitochondrial Proteins; Obesity; Pioglitazone; Proteins; Rats; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones; Uncoupling Protein 1 | 2000 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Therapy of type 2 diabetes. Blood lipids should not be neglected!].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Lipids; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; Gene Expression; Gene Expression Profiling; Hypoglycemic Agents; Liver; Mice; Muscles; Pioglitazone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Culture Techniques; Glucose Transporter Type 4; Humans; Insulin; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Phosphoproteins; Pioglitazone; Protein Isoforms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Mixed Function Oxygenases; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.
Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation | 2001 |
Honing type 2 diabetes treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazoles; Thiazolidinediones | 2001 |
Survival activity of troglitazone in rat motoneurones.
Topics: Animals; Antioxidants; Brain-Derived Neurotrophic Factor; Cell Survival; Cells, Cultured; Chromans; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Hippocampus; Insulin-Like Growth Factor I; Motor Neurons; Neurons, Afferent; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Rats; Receptors, Cytoplasmic and Nuclear; Septum of Brain; Spinal Cord; Sympathetic Nervous System; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[30-year-old diabetic patients mostly have type 2 diabetes. "Mature" diabetics are becoming increasingly younger].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Anticipated US approval for rosiglitazone and pioglitazone.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.
Topics: 3-Hydroxysteroid Dehydrogenases; Biguanides; Chromans; Cloning, Molecular; Humans; Kinetics; Metformin; Pioglitazone; Recombinant Proteins; Saccharomyces cerevisiae; Steroid 17-alpha-Hydroxylase; Steroid Hydroxylases; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
A comprehensive review of the antidiabetic agent rosiglitazone.
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Topics: Administration, Oral; Blood Glucose; Chromans; Dexamethasone; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Clearance Rate; Pioglitazone; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Deoxyglucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Transforming Growth Factor alpha | 2001 |
Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.
Topics: Asian People; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pioglitazone; Postprandial Period; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2001 |
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Genes, Tumor Suppressor; Humans; Phosphoric Monoester Hydrolases; Pioglitazone; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation | 2001 |
Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; DNA Primers; Enzyme-Linked Immunosorbent Assay; Gastric Mucosa; Hypoglycemic Agents; Inflammation; Male; Neutrophil Infiltration; Pioglitazone; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2001 |
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cell Division; Dose-Response Relationship, Drug; Gene Expression Regulation; Mice; Pioglitazone; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
PPARgamma agonists for intestinal ischaemia.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Intestines; Ischemia; Middle Aged; Peroxisomes; Pioglitazone; Reperfusion Injury; Retroperitoneal Fibrosis; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia.
Topics: Animals; Apoptosis; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell Survival; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Hyperplasia; In Situ Nick-End Labeling; Interferon-gamma; Interleukin-1; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Tunica Intima | 2001 |
Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Topics: Chromans; Clinical Trials as Topic; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Cell Division; Cell Size; DNA; Fatty Acids, Nonesterified; Feeding Behavior; Female; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Imaging; Obesity; Pioglitazone; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Thinness; Triglycerides; Weight Gain | 2001 |
Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth.
Topics: Animals; Body Weight; Cell Division; Cells, Cultured; DNA Replication; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Nuclear Proteins; Phosphorylation; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones | 2001 |
Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.
Topics: Aged; Blotting, Western; Cell Division; Cell Line; Chromans; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Ligands; Male; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Troglitazone; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2001 |
Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Cattle; Cell Division; Cells, Cultured; Chromans; Coronary Vessels; Dose-Response Relationship, Drug; Endothelins; Endothelium, Vascular; Gene Expression; Humans; Hypoglycemic Agents; Natriuretic Peptide, C-Type; Pioglitazone; Radioimmunoassay; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vasodilator Agents; Vasomotor System | 2001 |
PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells.
Topics: Animals; Arteriosclerosis; Cattle; Cells, Cultured; Chromans; Drug Antagonism; Endothelium; Immunohistochemistry; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone; Tumor Necrosis Factor-alpha | 2001 |
Hepatocellular injury in a patient receiving pioglitazone.
Topics: Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Division; Chromans; Coloring Agents; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Immunohistochemistry; Immunologic Factors; Kidney Neoplasms; Ligands; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured; Up-Regulation | 2001 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease Progression; Enzyme Activation; Glomerular Mesangium; Isoenzymes; Mice; Mitogen-Activated Protein Kinases; Pioglitazone; Plant Proteins; Protein Kinase C; Protein Kinase C beta; Rats; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoid Tumor; Cell Count; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Humans; Hypoglycemic Agents; In Vitro Techniques; Membrane Glycoproteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Thiazolidinediones; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.
Topics: Androstadienes; Animals; Cells, Cultured; Chromans; Enzyme Activation; Enzyme Inhibitors; Immunologic Factors; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pioglitazone; Prostaglandin D2; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Thymidine; Transcription Factors; Troglitazone; Wortmannin | 2001 |
Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.
Topics: Animals; Blood Glucose; Collagen; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; Hemodynamics; Hypoglycemic Agents; Insulin; Kinetics; Lipids; Male; Malondialdehyde; Oxidative Stress; Pioglitazone; Prediabetic State; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Ventricular Dysfunction, Left | 2001 |
Nonhypoglycemic effects of thiazolidinediones.
Topics: Adipocytes; Humans; Hypoglycemic Agents; Osteogenesis; Osteoporosis; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured | 2001 |
[Drug interactions as exemplified by thiazolidinediones (glitazones). Commentary on the publication of Ulrich Klotz and Dietmar Sailer, "Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)"Arz
Topics: Animals; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Survival Rate; Thiazoles; Thiazolidinediones | 2001 |
Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis.
Topics: Adipocytes; Animals; Antigens, Differentiation; Arsenites; Carcinogens; Carrier Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; Drug Antagonism; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Mice; Mice, Inbred C3H; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Sodium Compounds; Thiazoles; Thiazolidinediones; Transcription Factor AP-2; Transcription Factors; Up-Regulation | 2002 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Angioneurotic edema as a side effect of pioglitazone.
Topics: Angioedema; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.
Topics: Actins; Animals; Carbon Tetrachloride; Cells, Cultured; Collagen Type I; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Hypoglycemic Agents; Inflammation; Liver; Liver Cirrhosis; Necrosis; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Pioglitazone-associated fulminant hepatic failure.
Topics: Aged; Biopsy, Needle; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Pioglitazone; Risk Assessment; Thiazoles; Thiazolidinediones | 2002 |
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Adult; Asian People; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Pioglitazone; Proteins; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Transaminases | 2002 |
"Did this drug cause my patient's hepatitis?" and related questions.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Internal Medicine; Male; Middle Aged; Patient Care Planning; Physician's Role; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Transaminases | 2002 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
A peroxisome proliferator-activated receptor gamma agonist influenced daily profile of energy expenditure in genetically obese diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Hypoglycemic Agents; Leptin; Lipids; Obesity; Organ Size; Pancreas; Pioglitazone; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sample Size; Thiazoles; Thiazolidinediones | 2002 |
Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma.
Topics: Apoptosis; Cell Cycle; Cell Division; Cell Survival; Chondrosarcoma; Flow Cytometry; Humans; Male; Microscopy, Electron; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 2002 |
Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Eating; Glycogen; Hypoglycemic Agents; Ketone Bodies; Liver; Male; Metformin; Muscle, Skeletal; Obesity; Organ Size; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Proteins; Cell Division; Collagen; DNA; Drug Administration Schedule; Endothelium, Vascular; In Vitro Techniques; Inflammation; Injections, Subcutaneous; Lipids; Male; NF-kappa B; Pioglitazone; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents; Vasodilator Agents | 2002 |
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.
Topics: Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Markov Chains; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages.
Topics: Cell Differentiation; Cell Line; Cholesterol; Chromans; Coenzyme A Ligases; DNA, Antisense; Dose-Response Relationship, Drug; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Synthase; Macrophages; Oligonucleotides; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Response Elements; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2002 |
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Regression Analysis; Thiazoles; Thiazolidinediones | 2002 |
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Topics: Animals; Benzhydryl Compounds; Bile Ducts; Carbon Tetrachloride; Cell Division; Cells, Cultured; Collagen; Dimethylnitrosamine; DNA; Epoxy Compounds; Fibronectins; Hypoglycemic Agents; Ligation; Liver; Liver Cirrhosis; Male; Phenols; Pioglitazone; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
Topics: Anticholesteremic Agents; Blood Glucose; Body Weight; California; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
Topics: Animals; Dietary Fats; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pancreas; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Wistar; Rats, Zucker; Streptozocin; Thiazoles; Thiazolidinediones | 2002 |
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods.
Topics: Chromatography, High Pressure Liquid; Chromatography, Micellar Electrokinetic Capillary; Drug Contamination; Hypoglycemic Agents; Pharmaceutical Preparations; Pioglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant.
Topics: Animals; beta Catenin; Cytoskeletal Proteins; Endothelium; Kidney; Mice; Phenotype; Pioglitazone; Polycystic Kidney, Autosomal Dominant; Proteins; Proto-Oncogene Proteins c-myc; Sequence Deletion; Thiazoles; Thiazolidinediones; Trans-Activators; TRPP Cation Channels | 2002 |
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Topics: Animals; Cerebellum; Cerebral Cortex; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Female; Glycoproteins; Humans; Hypoglycemic Agents; I-kappa B Proteins; Ligands; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxazoles; Peptide Fragments; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Remission Induction; Spinal Cord; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2002 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Cell Count; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Homovanillic Acid; Hypoglycemic Agents; Immunohistochemistry; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Neuroglia; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Substantia Nigra; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine 3-Monooxygenase | 2002 |
Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Dietary Sucrose; Fructose; Hypertension; Hypoglycemic Agents; Kidney Cortex; Kidney Medulla; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium Chloride, Dietary; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Blood Platelets; COS Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Erythrocytes; Hybridization, Genetic; Hypoglycemic Agents; Macrophages; Male; Mice; Mice, Inbred Strains; Mononuclear Phagocyte System; Phagocytosis; Pioglitazone; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Thiazoles; Thiazolidinediones | 2002 |
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic Peptide, Brain; Pioglitazone; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stimulation, Chemical; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Pioglitazone; Proinsulin; Thiazoles; Thiazolidinediones | 2002 |
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dinoprostone; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Immunohistochemistry; Ligands; Male; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Testicular Neoplasms; Testis; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2002 |
Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone.
Topics: Animals; Base Sequence; Blotting, Northern; CD36 Antigens; DNA Primers; Glucose; Hypoglycemic Agents; Insulin; Membrane Glycoproteins; Muscle, Skeletal; Organic Anion Transporters; Pharmacogenetics; Pioglitazone; Rats; Rats, Inbred SHR; Sequence Deletion; Thiazoles; Thiazolidinediones | 2002 |
Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Glucose; Blood Pressure; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Inflammation; Insulin; Lipids; Male; Monocytes; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Peptidyl-Dipeptidase A; Pioglitazone; Rats; Rats, Inbred WKY; Receptors, CCR2; Receptors, Chemokine; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome | 2002 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
[Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Prognosis; Thiazoles; Thiazolidinediones | 2002 |
Severe but reversible cholestatic liver injury after pioglitazone therapy.
Topics: Cholestasis; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Topics: Acyl Coenzyme A; Adiponectin; Animals; Blood Glucose; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Heparin; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Phosphorylation; Pioglitazone; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone: effect on CYP3A4 activity.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Hydrocortisone; Hypoglycemic Agents; Male; Pioglitazone; Prospective Studies; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Blood Glucose; Cytokines; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Echocardiography; Gene Expression; Heart Failure; Heart Ventricles; Hemodynamics; Male; Matrix Metalloproteinase 9; Mice; Myocardial Infarction; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Observer Variation; Organ Size; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Reproducibility of Results; RNA, Messenger; Survival Rate; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Dysfunction, Left; Ventricular Remodeling | 2002 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th2 Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes.
Topics: Animals; Animals, Newborn; Astrocytes; Carbazoles; Cells, Cultured; Cerebral Cortex; Enzyme Inhibitors; Glucose; Glucose Transporter Type 1; Glycolysis; Hypoglycemic Agents; In Vitro Techniques; Indoles; Kinetics; Lactates; Monosaccharide Transport Proteins; Pioglitazone; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Mexican Americans; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; White People | 2003 |
Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal; Astrocytes; Cells, Cultured; Complement System Proteins; Crystallins; Demyelinating Diseases; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Glyceraldehyde-3-Phosphate Dehydrogenases; Heat-Shock Proteins; Heme Oxygenase (Decyclizing); Hypoglycemic Agents; Immunoglobulin G; In Vitro Techniques; Inflammation Mediators; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Neuroglia; Oxygenases; Pioglitazone; Rats; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2003 |
Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adenoviridae; Adipocytes; Animals; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation; Genetic Vectors; Mice; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Response Elements; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 2003 |
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
Topics: Adipocytes; Adipose Tissue; Anilides; Cell Differentiation; Cells, Cultured; Contraindications; Graves Disease; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postmarketing; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Female; Immunohistochemistry; Ligands; Mice; Mice, Inbred BALB C; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hypoglycemic Agents; Isometric Contraction; Lipid Peroxidation; Lipids; Male; Metformin; Muscle Contraction; Muscle Relaxation; Oxidation-Reduction; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2003 |
[Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma].
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Cyclophosphamide; Female; Hemangiopericytoma; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Lactones; Liver Neoplasms; Pioglitazone; Prednisolone; Recurrence; Sulfones; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Initial management of glycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone.
Topics: Antibodies, Monoclonal; Blotting, Northern; CD4 Antigens; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Gene Expression Regulation; HL-60 Cells; Humans; Lipopolysaccharide Receptors; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Thrombomodulin; Thromboplastin; Transcription Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |
[What is to be made of the therapy of borreliosis with cholestyramine and pioglitazone?].
Topics: Anti-Bacterial Agents; Cholestyramine Resin; Chronic Disease; Humans; Lyme Disease; Neurotoxins; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.
Topics: Adipocytes; Adrenergic beta-Agonists; Animals; Cells, Cultured; Cyclic AMP; Enzyme Activation; Esterification; Fatty Acids; Female; Gene Expression; Glycerol; Glycerol Kinase; Homeostasis; Hypoglycemic Agents; Isoproterenol; Lipid Metabolism; Lipolysis; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Pyruvic Acid; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Viscera | 2003 |
Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats.
Topics: Age Factors; Animals; Aorta; Body Weight; Collagen; Diabetes Mellitus, Type 2; Hemodynamics; Hypoglycemic Agents; Male; Oxidative Stress; Pioglitazone; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones | 2002 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Vascular smooth muscle cell activation by C-reactive protein.
Topics: Analysis of Variance; Animals; C-Reactive Protein; Cells, Cultured; Chemokine CCL2; Enzyme Activation; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Pioglitazone; Pyridines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors | 2003 |
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Topics: Animals; Bezafibrate; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Glucose; Glucose Transporter Type 2; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monosaccharide Transport Proteins; Pancreas; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade.
Topics: Animals; Anticoagulants; Body Weight; Colitis; Colon; Dextran Sulfate; DNA; Female; Hypoglycemic Agents; Inflammation; Ligands; Mice; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pioglitazone; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Time Factors; Transcription Factors | 2002 |
Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Intestinal Mucosa; Ligands; Male; Neutrophils; Peroxidase; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats.
Topics: Animals; Chemokines; Chemokines, CXC; Chemotactic Factors; Dose-Response Relationship, Drug; Gastric Mucosa; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Ligands; Lipid Peroxidation; Male; Peroxidase; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Time Factors; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
[A case of drug induced liver injury related pioglitazone].
Topics: Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma.
Topics: Adipose Tissue; Animals; Blood Glucose; Epididymis; Extremities; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Ion Channels; Leptin; Lipoprotein Lipase; Male; Membrane Transport Proteins; Mice; Mitochondrial Proteins; Muscle, Skeletal; Organ Specificity; Pioglitazone; Protein Biosynthesis; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Uncoupling Protein 2 | 2003 |
Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.
Topics: Becaplermin; Cell Count; Cell Cycle; Cell Division; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Ligands; Mammary Arteries; Mitogens; Muscle, Smooth, Vascular; Phosphorylation; Pioglitazone; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Radial Artery; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Saphenous Vein; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Protective effect of pioglitazone against multiple low-dose streptozotocin-induced diabetes in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Hypoglycemic Agents; Pioglitazone; Rats; Rats, Sprague-Dawley; Streptozocin; Thiazoles; Thiazolidinediones | 2003 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lipid Metabolism; Male; Middle Aged; Pioglitazone; Racial Groups; Splanchnic Circulation; Texas; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.
Topics: Amino Acid Sequence; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Gastric Mucosa; Hypoglycemic Agents; Interleukin-1; Isoenzymes; Leptin; Male; Membrane Proteins; Models, Animal; Pioglitazone; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; Splanchnic Circulation; Stomach Ulcer; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone.
Topics: Animals; Calcium; Drug Interactions; Ethanol; Female; Gene Expression; Hypoglycemic Agents; Kupffer Cells; Lipopolysaccharide Receptors; Lipopolysaccharides; Liver Diseases, Alcoholic; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells.
Topics: Adenoviridae; Animals; Cell Line; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Glucose; Hypoglycemic Agents; Immunoblotting; Immunohistochemistry; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Pioglitazone; Proinsulin; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Humans; Ibuprofen; Mice; Mice, Transgenic; Microglia; Peptide Fragments; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Glitazones and heart failure: critical appraisal for the clinician.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Eating; Energy Metabolism; Fenofibrate; Gene Expression; Glucose Tolerance Test; Glycated Hemoglobin; Homeostasis; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Lipids; Liver; Male; Obesity; Organ Size; Oxazines; Phenylpropionates; Pioglitazone; Rats; Rats, Mutant Strains; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2003 |
Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.
Topics: Blotting, Northern; Bronchi; Bronchitis; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Humans; Hypoglycemic Agents; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Respiratory Mucosa; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2003 |
A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Cells, Cultured; Glucose; Glucose Tolerance Test; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipoprotein Lipase; Male; Mice; Mice, Inbred ICR; Mice, Nude; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Topics: Animals; Disease Models, Animal; Heart Failure; Humans; Ligands; Mice; Myocardial Infarction; Pioglitazone; PPAR gamma; Rats; Thiazoles; Thiazolidinediones | 2004 |
MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
Topics: Animals; Benzamides; Blood Glucose; Chlorocebus aethiops; Cholesterol; COS Cells; Cricetinae; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Obese; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Simvastatin; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Transcriptional Activation; Triglycerides | 2004 |
Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Biological Transport; Blood Glucose; Cell Differentiation; Deoxyglucose; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Pioglitazone; PPAR gamma; Thiazoles; Thiazolidinediones; Triglycerides | 2004 |
Differential regulation and properties of angiopoietin-like proteins 3 and 4.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-Like Protein 4; Angiopoietin-like Proteins; Angiopoietins; Animals; Blood Proteins; Fenofibrate; Food Deprivation; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Male; Mice; Pioglitazone; PPAR alpha; PPAR delta; PPAR gamma; Protein Structure, Quaternary; Thiazoles; Thiazolidinediones | 2005 |
[Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance].
Topics: Adipose Tissue; Animals; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pioglitazone; Piperazines; Sulfonamides; Thiazoles; Thiazolidinediones | 2008 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models.
Topics: Analysis of Variance; Animals; Annexin A5; Antineoplastic Agents; bcl-2-Associated X Protein; Brain Neoplasms; Bromodeoxyuridine; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioma; Humans; Ligands; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Pioglitazone; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rats; Retinoid X Receptor gamma; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Transfection; Tretinoin; Tumor Stem Cell Assay | 2009 |
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Topics: Anilides; Animals; Benzamides; Biological Transport; Cell Survival; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Hypoglycemic Agents; Insulin; Membrane Potentials; Pioglitazone; PPAR gamma; Pyridines; Rosiglitazone; Sodium; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone | 2009 |
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins.
Topics: Animals; Bone Morphogenetic Proteins; Carrier Proteins; Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodendroglia; Pioglitazone; PPAR delta; Stem Cells; Thiazoles; Thiazolidinediones | 2010 |
Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action.
Topics: Apoptosis; Cells, Cultured; Cytoprotection; Electron Transport Complex IV; Gemfibrozil; Humans; Membrane Potentials; Mitochondrial Turnover; Necrosis; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Podocytes; Thiazoles; Thiazolidinediones | 2012 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibrate; Genome-Wide Association Study; Humans; Liver; Male; Mice; Phenylpropionates; Pioglitazone; Polymorphism, Single Nucleotide; PPAR alpha; PPAR gamma; Thiazoles; Thiazolidinediones | 2015 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer Tyrosine Kinase; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Leukocyte Common Antigens; Macrophages; Male; Membrane Glycoproteins; Mice; Microglia; Myeloid Cells; Phagocytosis; Pioglitazone; Plaque, Amyloid; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones | 2015 |
The mitochondrial outer membrane protein mitoNEET is a redox enzyme catalyzing electron transfer from FMNH
Topics: Electron Spin Resonance Spectroscopy; Electron Transport; Energy Metabolism; Escherichia coli Proteins; Flavin Mononucleotide; FMN Reductase; Humans; Hydroquinones; Hypoglycemic Agents; Kinetics; Mitochondrial Membranes; Mitochondrial Proteins; Oxidation-Reduction; Peptide Fragments; Pioglitazone; Recombinant Proteins; Thiazoles; Thiazolidinediones; Ubiquinone | 2017 |
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones | 2018 |
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism.
Topics: Acetanilides; Adipose Tissue, Beige; Drug Synergism; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Pioglitazone; Thiazoles | 2021 |